Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 193INDUSTRY 130NIH 18OTHER_GOV 6NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Lymphoid 3Gastrointestinal 2Dermatologic 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1Genitourinary 1CNS 1

Conditions

Gastric and Esophagogastric Junction Adenocarcinoma 1Colorectal Neoplasms 1

Interventions

Fluorouracil 74Leucovorin 48Oxaliplatin 44Cisplatin 40Capecitabine 39Gemcitabine 37Radiotherapy 30Irinotecan 28Cetuximab 21Paclitaxel 15Bevacizumab 12Docetaxel 10Taxes 9durvalumab 8dehydroftorafur 8Surgical Procedures, Operative 8Mitomycin 8Specimen Handling 7Platinum 7Folfox protocol 7Carboplatin 7Albumin-Bound Paclitaxel 7130-nm albumin-bound paclitaxel 7S 1 (combination) 6Panitumumab 6Watchful Waiting 5Imatinib Mesylate 5Gene Expression Profiling 5Epirubicin 5tremelimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Nivolumab × Gastrointestinal × Clear all
NCT03443856 2024-01-05

VESTIGE

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Active not recruiting
197 enrolled
Gastrointestinal

Gastric and Esophagogastric Junction Adenocarcinoma

NCT03647839 2021-08-27

MODULATE

Australasian Gastro-Intestinal Trials Group

Phase 2 Completed
90 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡